Does Rallies show 13F holders for SLNO?

Yes. Rallies tracks hedge fund and 13F ownership data for SLNO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SLNO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SLNO. It does not provide personalized investment advice.

SLNO (Soleno Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Soleno Therapeutics, Inc. Common Stock (SLNO) is a publicly traded Healthcare sector company. As of May 21, 2026, SLNO trades at $53.01 with a market cap of $2.76B and a P/E ratio of 132.53. SLNO moved +0.01% today. Year to date, SLNO is +14.52%; over the trailing twelve months it is -29.39%. Its 52-week range spans $29.43 to $90.32. Analyst consensus is neutral with an average price target of $61.00. Rallies surfaces SLNO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SLNO stock?

Hedge funds tracked by Rallies that own SLNO include Soros Fund, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Soleno Therapeutics, Inc. Common Stock.

SLNO Key Metrics

Key financial metrics for SLNO
Metric	Value
Price	$53.01
Market Cap	$2.76B
P/E Ratio	132.53
EPS	$0.40
Dividend Yield	0.00%
52-Week High	$90.32
52-Week Low	$29.43
Volume	0
Avg Volume	0
Revenue (TTM)	$190.41M
Net Income	$20.89M
Gross Margin	98.58%

Top Hedge Funds Holding SLNO

Soros Fund holds 270.66K shares of SLNO, changed +146.06% as of Mar 31, 2025.
Centerbook Partners holds 62.79K shares of SLNO, changed +156.18% as of Sep 30, 2025.
Farallon Capital holds 5.00K shares of SLNO, changed -98.37% as of Dec 31, 2025.

Latest SLNO News

Halper Sadeh Targets Soleno Therapeutics $53 Per Share Sale to Neurocrine — Apr 23, 2026
Neurocrine to Acquire Soleno Therapeutics for $2.9B at 34% Premium — Apr 12, 2026
Soleno Therapeutics' $53/share Sale to Neurocrine Sparks Fiduciary Probe — Apr 10, 2026
Neurocrine to Acquire Soleno for $53 per Share, 34% Premium — Apr 6, 2026
Soleno Therapeutics' Price Targets Slashed to $110 and $85 After Q4 Surge — Mar 1, 2026

Recent SLNO Insider Trades

Manning Meredith sold 4.86K (~$146.10K) on Mar 27, 2026.
Manning Meredith sold 2.10K (~$65.18K) on Mar 27, 2026.
Manning Meredith sold 558 (~$17.70K) on Mar 27, 2026.

SLNO Analyst Consensus

12 analysts cover SLNO: 0 strong buy, 1 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $61.00.

Common questions about SLNO

Who owns SLNO stock?: Hedge funds tracked by Rallies that own SLNO include Soros Fund, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Soleno Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for SLNO?: Yes. Rallies tracks hedge fund and 13F ownership data for SLNO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SLNO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SLNO. It does not provide personalized investment advice.